Lu177labeled
Lu-177 labeled compounds are radiopharmaceuticals in which lutetium-177 is bound to a biological targeting molecule via a chelator, most commonly DOTA. The resulting agents deliver targeted beta radiation to tumor tissue while emitting gamma photons that enable imaging, supporting diagnostic monitoring and dosimetry. This combination of therapy and imaging gives rise to a theranostic approach in nuclear medicine.
Commonly used chelators and vectors define the landscape of Lu-177 labeling. DOTA forms stable complexes with
Production and physical properties of Lu-177 are well established. The isotope has a half-life of about 6.65
Clinical use and regulatory status include several approved Lu-177 therapies. 177Lu-DOTATATE (Lutathera) is approved for unresectable
Safety considerations include potential hematologic suppression, renal toxicity, dry mouth, and nausea. Treatment requires specialized facilities